| 0.876 -0.154 (-14.95%) | 06-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.89  |
1-year : | 4.06 |
| Resists | First : | 2.48 |
Second : | 3.48 |
| Pivot price | 1.15 |
|||
| Supports | First : | 0.86 |
Second : | 0.72 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.3 |
| MA(100) : | 0.83 |
MA(250) : | 2.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 14.3 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 7.34 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HCWB ] has closed below the lower bollinger band by 4.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.08 | 1.08 - 1.09 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.87 - 0.88 | 0.88 - 0.88 |
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Fri, 26 Jun 2026
HCW Biologics Inc (HCWB) Stock Price, Quote, News & History - Benzinga
Fri, 26 Jun 2026
HCW Biologics (NASDAQ: HCWB) enacts 1-for-6 reverse split to support Nasdaq bid-price compliance - Stock Titan
Fri, 26 Jun 2026
HCW Biologics cuts shares 1-for-6 to avoid Nasdaq delisting - Stock Titan
Fri, 26 Jun 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - GlobeNewswire
Thu, 25 Jun 2026
HCW Biologics, Inc. Actuals & Estimates (NASDAQ:HCWB) - TradingView
Mon, 22 Jun 2026
[EFFECT] HCW Biologics Inc. SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 5.85e+006 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 3,840 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.7e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -34.8 % |
| Operating Margin | 49.4 % |
| Return on Assets (ttm) | -15.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 129 % |
| Gross Profit (p.s.) | 36.51 |
| Sales Per Share | 2.9819e+006 |
| EBITDA (p.s.) | 2.95928e+006 |
| Qtrly Earnings Growth | -8.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.25 |
| Dividend | 0 |
| Forward Dividend | 296810 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|